Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Current Assets (2016 - 2025)

Immucell (ICCC) has disclosed Current Assets for 16 consecutive years, with $16.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 21.15% year-over-year to $16.8 million, compared with a TTM value of $16.8 million through Sep 2025, up 21.15%, and an annual FY2024 reading of $15.0 million, up 31.15% over the prior year.
  • Current Assets was $16.8 million for Q3 2025 at Immucell, down from $17.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $18.3 million in Q1 2022 and bottomed at $10.8 million in Q2 2024.
  • Average Current Assets over 5 years is $14.4 million, with a median of $15.0 million recorded in 2024.
  • The sharpest move saw Current Assets soared 61.77% in 2021, then plummeted 36.83% in 2023.
  • Year by year, Current Assets stood at $16.3 million in 2021, then fell by 13.96% to $14.0 million in 2022, then decreased by 18.04% to $11.5 million in 2023, then skyrocketed by 31.15% to $15.0 million in 2024, then rose by 11.85% to $16.8 million in 2025.
  • Business Quant data shows Current Assets for ICCC at $16.8 million in Q3 2025, $17.1 million in Q2 2025, and $15.9 million in Q1 2025.